Navigation Links
Common ancestry of bacterium and plants could be key to an effective new treatment for chlamydia

Rutgers researchers have discovered that the Chlamydia bacterium, which causes a sexually transmitted disease (STD), shares an evolutionary heritage with plants. That shared evolutionary heritage, which is not found in most other bacteria, points to a prime target for development of an effective cure for Chlamydia infections.

"The unique connection between the Chlamydia bacterium and plants had been proposed by others," said Thomas Leustek," a professor in the department of plant biology and pathology at Rutgers' School of Environmental and Biological Sciences (formerly Cook College). "But we have now described a specific example demonstrating the common heritage. That specific example, an enzyme that supports protein production, could lead to antibiotics specific for this form of STD."

The discovery is an unexpected turn in solving the mystery of how plants produce lysine, one of the 20 amino acids normally found in proteins. Scientists have known the specific pathways of lysine production in bacteria for more than a half-century. They also have known some of the steps by which lysine is produced in plants, but they didn't really have the full picture. Leustek and Andre Hudson, a postdoc working in Leustek's lab in Rutgers' Biotechnology Center for Agriculture and the Environment, were able to solve the pathway when they discovered the gene encoding the enzyme L,L-diaminopimelate aminotransferase from the plant Arabdiopsis thaliana. The results of this discovery were published in the journal Plant Physiology in January 2006.

The gene that Leustek and Hudson had discovered was unmistakably similar to a sequence that Anthony Maurelli of the Uniformed Services University of the Health Sciences in Bethesda, Md., had detected in Chlamydia. "Further experimentation confirmed that the Chlamydial gene had the same function as the Arabidopisis gene demonstrating their common ancestry," said Leustek. "If they had evolved separately, it would be imp ossible for the sequences to match so closely."

The ability to easily compare plants and bacteria is the result of genome sequencing, which has decoded the complete genetic blueprint for entire species. "This would not have been possible 10 years ago," said Leustek. "But now we have access to more that 500 different genomes in a data base. After having identified a gene in plants, I can quickly identify the homologous gene from any bacteria in the database. As a plant biologist I wouldn't have ever imagined that I would be working with Chlamydia. Yet, with the help of genomics I found myself working with a collaborator and publishing a paper in that area."

Their experiments revealed that in addition to sharing genome sequences, Chlamydia and plants share similar functions as well. Furthermore, they found that the pathway used by plants to produce lysine is probably used by Chlamydia to synthesize a chemical found in bacterial cell walls. It is the synthesis of cell walls that is inhibited by penicillin. This discovery points to the likelihood that, if researchers could find an inhibitor for L,L-diaminopimelate aminotransferase they would have a new antibiotic that would target Chlamydia.

Chlamydia trachomatis is a bacteria that is responsible for a common STD. If untreated, Chlamydia infections can damage a woman's reproductive organs and lead to infertility. An estimated 2.8 million men and women in the U.S. are infected with chlamydia each year. Chlamydia can be easily treated and cured with antibiotics. However, bacteria often develop resistance to antibiotics, meaning that new ones must be continually discovered. Moreover, an inhibitor to L,L-diaminopimelate aminotransferase would be very specific for Chlamydia since this enzyme has not been found in any bacteria that live with humans.

So the hunt for a new antibiotic is on. Leustek is going to start screening for chemicals that block the enzyme. He is also using the res ults of his research to work on another approach, which is to characterize the structure of the enzyme so that he could design an antibiotic that would disable the pathway. This approach is somewhat like designing a key to fit a lock by opening the lock and looking inside.

The research is being done in collaboration with Charles Gilvarg from Princeton University. "He's the biochemist who characterized the lysine pathway back in the 1950s, and so he had intimate knowledge about the steps of the pathway," said Leustek. "And he's the one that alerted us to the fact that plants do it differently. This is still the case, with the exception of the Chlamydia bacterium."
'"/>

Source:Rutgers, the State University of New Jersey


Related biology news :

1. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
2. Harmful Bacterium Commonly Found in Poultry May Survive Refrigeration and Frozen Storage Combined
3. Men Estimate Mens Risks Of Common Disorders Higher Than Women Do, And Vice Versa
4. Use of Antibiotics for Acne May Increase Risk of Common Illness
5. Common viruses may cause cancer
6. Common alternative treatment for liver disease is found to be ineffective
7. Common molecular signature identified in solid tumors
8. Common bacteria pirate natural mechanism to get inside cells
9. Commonly used antidepressants may also affect human immune system
10. Common practices at petting zoos put visitors at risk
11. Common enzyme is a key player in DNA repair

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: